Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL19P1 is a processed pseudogene corresponding to the ribosomal protein L19 (RPL19) gene. Pseudogenes such as RPL19P1 arise from genomic duplications or retrotransposition events. They resemble functional genes but are generally non-coding and do not produce functional proteins. RPL19P1 is not known to play a direct biological, pathological, or therapeutic role; it does not act as a receptor, enzyme, transporter, or transcription factor. There are multiple ribosomal pseudogenes like RPL19P1 in the human genome, typically classified as "processed pseudogenes"[1][4][5][8]. RPL19P1 is not referenced in the literature as a therapeutic target, drug interactor, or disease biomarker, and there is no evidence supporting a role in pathogenesis or therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L19 pseudogene 1 (RPL19P1).